Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center